MedTrace Logo

"Phospholipovit" vs Placebo in Patients With Combined Hyperlipidemia

NCT05742022 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-02-23

No results posted yet for this study

Summary

"Phospholipovit" vs placebo in patients with combined hyperlipidemia

Conditions

  • Combined Hyperlipidemia

Interventions

DRUG

"Phospholipovit"

500 mg orally 2 times a day, for 12 weeks

DRUG

Placebo

500 mg orally 2 times a day, for 12 weeks

Sponsors & Collaborators

  • Institute of Biomedical Chemistry, Russia

    lead OTHER

Principal Investigators

  • Alexander I. Archakov, MD, PhD · Institute of Biomedical Chemistry

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2018-06-20
Completion
2022-12-20

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05742022 on ClinicalTrials.gov